Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 23, Pages -Publisher
MDPI
DOI: 10.3390/jcm10235614
Keywords
adjuvant; immune checkpoint inhibitors; immunotherapy; neoadjuvant; non-small-cell lung cancer (NSCLC)
Categories
Ask authors/readers for more resources
Immunotherapy is considered a novel approach to improve survival in early-stage non-small-cell lung cancer patients, but there are still unresolved issues such as predictive markers, optimal combination therapy, and the need for adjuvant immunotherapy. More studies are needed to optimize the treatment regimen for immunotherapy in early-stage NSCLC.
Lung cancer is worldwide the most common malignancy. Standard of care treatments for early-stage non-small-cell lung cancer (NSCLC) include surgery and adjuvant chemotherapy. However, these patients continue to have poor prognosis due to systemic or local relapse. Immunotherapy has been considered as a novel approach to improve survival in patients with early-stage NSCLC. Since immune checkpoint inhibitors have transformed the treatment of advanced NSCLC, there is a growing interest in the role of immunotherapy in early-stage NSCLC. In this review, we summarize reported and ongoing clinical trials of immunotherapy in both neoadjuvant and adjuvant settings. We also highlight unaddressed issues in this field of research, such as the predictive markers, the optimal combination therapy, and the need for adjuvant immunotherapy. More studies are needed to optimize the treatment regimen of immunotherapy in patients with early-stage NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available